Squarepoint
ACRS icon

Squarepoint’s Aclaris Therapeutics ACRS Stock Holding History

Squarepoint’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-390,583
Closed -$555K – 4311
2025
Q2 		$555K Buy
390,583
+41,666
+12% +$56.4K ﹤0.01% 3185
2025
Q1 		$534K Buy
348,917
+56,025
+19% +$120K ﹤0.01% 3237
2024
Q4 		$726K Buy
292,892
+152,312
+108% +$379K ﹤0.01% 3371
2024
Q3 		$162K Buy
140,580
+45,893
+48% +$56.3K ﹤0.01% 3761
2024
Q2 		$104K Buy
+94,687
New +$111K ﹤0.01% 3789
2024
Q1 		– Sell
-10,378
Closed -$10.9K – 3948
2023
Q4 		$10.9K Buy
+10,378
New +$31.7K ﹤0.01% 3927
2021
Q4 		– Sell
-15,834
Closed -$285K – 3114
2021
Q3 		$285K Buy
+15,834
New +$254K ﹤0.01% 2285
2021
Q2 		– Sell
-8,537
Closed -$215K – 3167
2021
Q1 		$215K Buy
+8,537
New +$167K ﹤0.01% 2660
2020
Q1 		– Sell
-83,924
Closed -$159K – 1802
2019
Q4 		$159K Buy
+83,924
New +$139K ﹤0.01% 2269
2019
Q3 		– Sell
-58,902
Closed -$129K – 2300
2019
Q2 		$129K Buy
58,902
+12,996
+28% +$70.8K ﹤0.01% 2189
2019
Q1 		$275K Sell
45,906
-66,684
-59% -$442K ﹤0.01% 1811
2018
Q4 		$832K Buy
112,590
+81,220
+259% +$837K 0.01% 995
2018
Q3 		$455K Buy
31,370
+16,995
+118% +$291K 0.01% 1344
2018
Q2 		$287K Sell
14,375
-24,683
-63% -$456K ﹤0.01% 1395
2018
Q1 		$684K Buy
39,058
+19,442
+99% +$412K 0.01% 965
2017
Q4 		$484K Buy
+19,616
New +$478K 0.01% 1230
2017
Q1 		– Sell
-10,739
Closed -$291K – 1487
2016
Q4 		$291K Buy
+10,739
New +$274K 0.01% 1167

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Squarepoint's ACRS Position: Q3 2025 in Review

Squarepoint sold out of Aclaris Therapeutics (ACRS) in Q3 2025, closing a stake of 390,583 shares — an estimated $555K sold.

Squarepoint first reported a position in ACRS in Q4 2016 and held it in 17 quarters. The position peaked at $832K in Q4 2018. 103 funds tracked by Wall St. Rank hold ACRS as of Q3 2025.

  • Squarepoint reported no remaining Aclaris Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Squarepoint sold 390,583 Aclaris Therapeutics shares in Q3 2025, an estimated $555K.
  • Squarepoint first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 17 quarters.
  • Squarepoint's Aclaris Therapeutics position peaked at $832K in Q4 2018.
  • 103 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.